Suchergebnisse - "Jones, John R"

PubPharm (6)

1

The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages : results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial

enthalten in: British journal of haematology | 2023

von Jenner, M. | Pawlyn, C. | Davies, F. | +16

2

Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial

enthalten in: Haematologica | 2021

von Jackson, G. | Davies, F. | Pawlyn, C. | +21

3

Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma : results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial

enthalten in: British journal of haematology | 2021

von Jackson, G. | Pawlyn, C. | Cairns, D. | +21

4

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+) : Interim analysis of an open-label randomised controlled trial

enthalten in: PLoS medicine | 2021

von Jackson, G. | Pawlyn, C. | Cairns, D. | +21

5

Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials

enthalten in: Blood | 2020

von Craig, Z. | Cook, G. | Pawlyn, C. | +13

CommentIn: Blood. 2020 Aug 27;136(9):1019-1021. - PMID 32853375

6

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI) : a multicentre, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Haematology | 2019

von Jackson, G. | Davies, F. | Pawlyn, C. | +20

1
[1]